Healthcare / Medical Care FacilitiesTokyo
$900.00
-3.00 (-0.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $382.0M · quality 25.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
37.4x
↑EV/EBITDA
7.4x
↓ROE
6.1%
↑Gross Margin
16.4%
↓Debt/Equity
3.09
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
7.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.13B · net income $110.0M · FCF $803.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.13B | $18.13B | $16.02B | $14.56B | $12.13B |
| Net Income | $110.0M | $110.0M | $-466.0M | $100.0M | $-27.0M |
| EBITDA | $974.0M | $974.0M | $275.0M | $620.0M | $498.0M |
| EPS | — | — | -102.03 | 21.91 | -5.99 |
| Gross Margin | 16.4% | 16.4% | 14.9% | 15.0% | 14.4% |
| Operating Margin | 3.5% | 3.5% | 1.2% | 1.3% | 1.3% |
| Net Margin | 0.6% | 0.6% | -2.9% | 0.7% | -0.2% |
| Balance Sheet | |||||
| Debt/Equity | 3.09 | 3.09 | 3.09 | 2.12 | 2.26 |
| Current Ratio | 0.90 | 0.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $803.0M | $803.0M | $382.0M | $-114.0M | $-145.0M |
| Returns | |||||
| ROE | 6.1% | 6.1% | -26.9% | 4.5% | -1.2% |
| Valuation | |||||
| P/E | 37.38 | 37.38 | — | 23.00 | — |
| EV/EBITDA | 7.36 | 7.36 | 19.27 | 8.29 | 10.78 |
| P/B | 2.28 | 2.28 | 1.21 | 1.03 | 1.20 |
| Growth & Yield | |||||
| Revenue Growth | 13.2% | 13.2% | 10.0% | 20.0% | — |
| EPS Growth | — | — | -565.7% | 465.8% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+85.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-102.03 → n/d
Residual
+83.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.